COVAXX Vaccine Prioritization Advisory Group Provides Guidelines for Equitable Deployment of COVID-19 Vaccine Doses To Emerging Countries

Hauppauge, New York--(Newsfile Corp. - December 23, 2020) - COVAXX, a U.S. company developing a multitope synthetic peptide-based vaccine to fight COVID-19, has established a Vaccine Prioritization Advisory Group (VPAG) to guide the company leadership on how best to apportion the first 100 million doses of the COVAXX COVID-19 vaccine.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Recent study from the Bill & Melinda Gates Foundation shows two-fold benefit worldwide with an equitable distribution of COVID-19 vaccines compared to prioritizing wealthy countries
• VPAG aimed to fulfill COVAXX's mission of Democratizing Health by providing guidance to support transparency, trust and efficiency in obtaining worldwide eradication of COVID-19

Click image above to view full announcement.

UB-612 Fact Sheet: www.covaxx.com/vaccine

About COVAXX. The mission of COVAXX is to democratize health and safeguard lives worldwide by tackling the global COVID-19 pandemic using cost-effective, scalable and proven science-based solutions. Produced from a commercially proven, vaccine platform, UB-612 is a multitope vaccine designed to activate both B and T-cell arms of the immune system. Preclinical studies have shown that the UB-612 vaccine candidate generated high titers of neutralizing antibodies.

COVAXX is a subsidiary of United Biomedical Inc (UBI), founded in 1985, with headquarters in New York. The company is a scientific trailblazer creating technological firsts, including the manufacture and commercialization of more than 100 million antibody blood diagnostic tests and 5 billion vaccine doses against infectious diseases in animal health. With proprietary access to UBI's core technology platforms, COVAXX can develop and commercialize high precision antibody tests and a promising COVID-19 vaccine that together would form a unique Differentiating Infected from Vaccinated Individuals (DIVI) system.

For more information, visit www.covaxx.com and follow us on social media. Twitter: @covaxxvaccine; Facebook: @COVAXX; LinkedIn: /COVAXX; and Instagram: @covaxxvaccine.

Contacts:

Diane Murphy
(310) 658.8756
diane@covaxx.com

David Schull
2128454226
David.Schull@russopartnersllc.com

Source: COVAXX

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70912